Skip to main content
Erschienen in: Discover Oncology 4/2015

01.08.2015 | Original Paper

Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth

verfasst von: M. J. Pineda, Z. Lu, D. Cao, J. J. Kim

Erschienen in: Discover Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Cancer-associated fibroblasts have been shown to inhibit or stimulate tumor growth depending on stage, grade, and tumor type. It remains unclear, however, the effect of endometrial-cancer-associated fibroblasts on hormone-driven responses in endometrial cancer. In this study, we investigated the effect of normal and cancer-associated stromal cells from patients with and without endometrial cancer on endometrial tumor growth in response to estradiol (E2) and progesterone (P4). Compared to benign endometrial stromal cells, the low-grade and high-grade cancer-associated stromal cells exhibited a blunted hormone response for proliferation as well as IGFBP1 secretion. Additional analysis of the influence of stromal cells on hormone-driven tumor growth was done by mixing stromal cells from benign, low-grade, or high-grade tumors, with Ishikawa cells for subcutaneous tumor formation. The presence of both benign and high-grade cancer-associated stromal cells increased estradiol-driven xenografted tumor growth compared to Ishikawa cells alone. Low-grade cancer-associated stromal cells did not significantly influence hormone-regulated tumor growth. Addition of P4 attenuated tumor growth in Ishikawa + benign or high-grade stromal cells, but not in Ishikawa cells alone or with low-grade stromal cells. Using an angiogenesis focused real-time array TGFA, TGFB2 and TGFBR1 and VEGFC were identified as potential candidates for hormone-influenced growth regulation of tumors in the presence of benign and high-grade stromal cells. In summary, endometrial-cancer-associated cells responded differently to in vitro hormone treatment compared to benign endometrial stromal cells. Additionally, presence of stromal cells differentially influenced hormone-driven xenograft growth in vivo depending on the disease status of the stromal cells.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat American Cancer Society (2014) Cancer Facts Fig American Cancer Society (2014) Cancer Facts Fig
4.
Zurück zum Zitat Anzai Y, Gong Y, Holinka CF, Murphy LJ, Murphy LC, Kuramoto H, Gurpide E (1992) Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines. J Steroid Biochem Mol Biol 42(5):449–455PubMedCrossRef Anzai Y, Gong Y, Holinka CF, Murphy LJ, Murphy LC, Kuramoto H, Gurpide E (1992) Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines. J Steroid Biochem Mol Biol 42(5):449–455PubMedCrossRef
5.
Zurück zum Zitat Arnold JT, Kaufman DG, Seppala M, Lessey BA (2001) Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Hum Reprod 16(5):836–845PubMedCrossRef Arnold JT, Kaufman DG, Seppala M, Lessey BA (2001) Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Hum Reprod 16(5):836–845PubMedCrossRef
6.
Zurück zum Zitat Arnold JT, Lessey BA, Seppala M, Kaufman DG (2002) Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res 62(1):79–88PubMed Arnold JT, Lessey BA, Seppala M, Kaufman DG (2002) Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res 62(1):79–88PubMed
7.
Zurück zum Zitat Bausero P, Cavaille F, Meduri G, Freitas S, Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2(2):167–182PubMedCrossRef Bausero P, Cavaille F, Meduri G, Freitas S, Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2(2):167–182PubMedCrossRef
9.
Zurück zum Zitat Chegini N, Zhao Y, Williams RS, Flanders KC (1994) Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 135(1):439–449. doi:10.1210/endo.135.1.8013382 PubMed Chegini N, Zhao Y, Williams RS, Flanders KC (1994) Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 135(1):439–449. doi:10.​1210/​endo.​135.​1.​8013382 PubMed
10.
Zurück zum Zitat Cunha GR, Cooke PS, Kurita T (2004) Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67(5):417–434PubMedCrossRef Cunha GR, Cooke PS, Kurita T (2004) Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67(5):417–434PubMedCrossRef
14.
Zurück zum Zitat Felix AS, Weissfeld J, Edwards R, Linkov F (2010) Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur J Gynaecol Oncol 31(2):139–144PubMedCentralPubMed Felix AS, Weissfeld J, Edwards R, Linkov F (2010) Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur J Gynaecol Oncol 31(2):139–144PubMedCentralPubMed
16.
Zurück zum Zitat Girling JE, Rogers PA (2009) Regulation of endometrial vascular remodelling: role of the vascular endothelial growth factor family and the angiopoietin-TIE signalling system. Reproduction 138(6):883–893. doi:10.1530/REP-09-0147 PubMedCrossRef Girling JE, Rogers PA (2009) Regulation of endometrial vascular remodelling: role of the vascular endothelial growth factor family and the angiopoietin-TIE signalling system. Reproduction 138(6):883–893. doi:10.​1530/​REP-09-0147 PubMedCrossRef
17.
Zurück zum Zitat Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, Korc M, Demopoulos RI (1994) Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 54(9):2347–2358PubMed Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, Korc M, Demopoulos RI (1994) Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 54(9):2347–2358PubMed
19.
Zurück zum Zitat Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y et al (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956–1967. doi:10.1158/1535-7163.MCT-09-1012 PubMedCrossRef Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y et al (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956–1967. doi:10.​1158/​1535-7163.​MCT-09-1012 PubMedCrossRef
22.
Zurück zum Zitat Kurita T, Medina R, Schabel AB, Young P, Gama P, Parekh TV, Brody J et al (2005) The activation function-1 domain of estrogen receptor alpha in uterine stromal cells is required for mouse but not human uterine epithelial response to estrogen. Differentiation 73(6):313–322. doi:10.1111/j.1432-0436.2005.00033.x PubMedCrossRef Kurita T, Medina R, Schabel AB, Young P, Gama P, Parekh TV, Brody J et al (2005) The activation function-1 domain of estrogen receptor alpha in uterine stromal cells is required for mouse but not human uterine epithelial response to estrogen. Differentiation 73(6):313–322. doi:10.​1111/​j.​1432-0436.​2005.​00033.​x PubMedCrossRef
23.
Zurück zum Zitat Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O’Malley BW, Isaacs JT, Dahiya R, Cunha GR (2001) Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8(2):192–200. doi:10.1038/sj.cdd.4400797 PubMedCrossRef Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O’Malley BW, Isaacs JT, Dahiya R, Cunha GR (2001) Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8(2):192–200. doi:10.​1038/​sj.​cdd.​4400797 PubMedCrossRef
28.
Zurück zum Zitat Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309PubMedCrossRef Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309PubMedCrossRef
29.
Zurück zum Zitat Moller B, Lindblom B, Olovsson M (2002) Expression of the vascular endothelial growth factors B and C and their receptors in human endometrium during the menstrual cycle. Acta Obstet Gynecol Scand 81(9):817–824PubMedCrossRef Moller B, Lindblom B, Olovsson M (2002) Expression of the vascular endothelial growth factors B and C and their receptors in human endometrium during the menstrual cycle. Acta Obstet Gynecol Scand 81(9):817–824PubMedCrossRef
30.
Zurück zum Zitat Murphy LJ, Gong Y, Murphy LC (1992) Regulation of transforming growth factor gene expression in human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 41(3–8):309–314PubMedCrossRef Murphy LJ, Gong Y, Murphy LC (1992) Regulation of transforming growth factor gene expression in human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 41(3–8):309–314PubMedCrossRef
31.
32.
Zurück zum Zitat Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T (1996) Establishment of eighteen clones of Ishikawa cells. Hum Cell 9(2):109–116PubMed Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T (1996) Establishment of eighteen clones of Ishikawa cells. Hum Cell 9(2):109–116PubMed
33.
Zurück zum Zitat Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed
35.
Zurück zum Zitat Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45(2):268–272PubMedCrossRef Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45(2):268–272PubMedCrossRef
36.
Zurück zum Zitat Podratz KC, O’Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH (1985) Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66(1):106–110PubMed Podratz KC, O’Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH (1985) Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66(1):106–110PubMed
38.
Zurück zum Zitat Quinn MA, Cauchi M, Fortune D (1985) Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 21(3):314–319PubMedCrossRef Quinn MA, Cauchi M, Fortune D (1985) Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 21(3):314–319PubMedCrossRef
39.
Zurück zum Zitat Ripley D, Tang XM, Ma C, Chegini N (2001) The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma. Gynecol Oncol 81(2):301–309. doi:10.1006/gyno.2001.6161 PubMedCrossRef Ripley D, Tang XM, Ma C, Chegini N (2001) The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma. Gynecol Oncol 81(2):301–309. doi:10.​1006/​gyno.​2001.​6161 PubMedCrossRef
44.
Zurück zum Zitat Wu QW, She HQ, Liang J, Huang YF, Yang QM, Yang QL, Zhang ZM (2012) Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. BMC Cancer 12:47. doi:10.1186/1471-2407-12-47 PubMedCentralPubMedCrossRef Wu QW, She HQ, Liang J, Huang YF, Yang QM, Yang QL, Zhang ZM (2012) Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer. BMC Cancer 12:47. doi:10.​1186/​1471-2407-12-47 PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Xu H, Zhang T, Man GC, May KE, Becker CM, Davis TN, Kung AL et al (2013) Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis 16(3):541–551. doi:10.1007/s10456-013-9333-1 PubMedCrossRef Xu H, Zhang T, Man GC, May KE, Becker CM, Davis TN, Kung AL et al (2013) Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis 16(3):541–551. doi:10.​1007/​s10456-013-9333-1 PubMedCrossRef
Metadaten
Titel
Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth
verfasst von
M. J. Pineda
Z. Lu
D. Cao
J. J. Kim
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Discover Oncology / Ausgabe 4/2015
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-015-0223-4

Weitere Artikel der Ausgabe 4/2015

Discover Oncology 4/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.